<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664053</url>
  </required_header>
  <id_info>
    <org_study_id>AG0099</org_study_id>
    <secondary_id>NNG04GK63G</secondary_id>
    <nct_id>NCT00664053</nct_id>
  </id_info>
  <brief_title>Effects of DHEA/Exercise on Bone, Muscle and Balance</brief_title>
  <official_title>Effects of DHEA/Exercise on Bone, Muscle and Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Aeronautics and Space Administration (NASA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether muscle strength and balance will improve in
      women with frailty selected for dehydroepiandrosterone sulfate (DHEAS) levels below 550 ng/dl
      treated with DHEAS supplementation and Hatha yoga. Investigators believe the effects of both
      treatments will improve outcomes more than either treatment alone and may be additive; in
      addition, lean body mass, skeletal muscle mass, markers of bone turnover and physical
      performance will improve following treatment with DHEA and/or yoga.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dehydroepiandrosterone (DHEAS) and yoga may mitigate or reverse the effects of aging and
      frailty on bone, muscle and balance loss. The mechanism of the effects may be direct -
      working through androgen or estrogen receptors in bone, muscle or brain. Or the effects may
      be indirect, countering effects of the stress response.

      The specific aims of this study are:

        1. To determine the effects of dehydroepiandrosterone sulfate (DHEAS) supplementation
           and/or Hatha yoga on muscle strength, balance, body composition and physical performance
           measures over 6 months in women with osteopenia and some degree of frailty

        2. To determine the effect of dehydroepiandrosterone sulfate (DHEAS) supplementation and/or
           Hatha yoga on function (physical and cognitive), bone metabolism, and cardiovascular
           risk factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle strength, bone turnover markers</measure>
    <time_frame>baseline, 3 month and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in activities of daily living, cognitive and emotional function</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests to measure factors that may reflect or influence changes in bone metabolism</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Frailty</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA and Yoga</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHEA and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo and Yoga</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHEA</intervention_name>
    <description>50mg daily for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Dehydroepiandrosterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Yoga</intervention_name>
    <description>2 sessions per week for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement every day for 6 months</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Aerobics</intervention_name>
    <description>Walking/chair aerobics program 2 sessions per week for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over age 65 years

          -  Bone mineral density t-score less than -1

          -  At least one of the five components of the frailty phenotype (low hand grip strength,
             low walking speed, low physical activity, weight loss or sense of exhaustion)

          -  DHEAS levels less than 550 ng/dl

          -  Able to come or be brought to the University of Connecticut Health Center (UCHC) for
             outpatient visits

          -  Mammogram within the preceding 12 months

        Exclusion Criteria:

          -  Disease or medication known to affect bone or muscle metabolism (i.e., Paget's
             disease, osteomalacia or 25OHD level less than 10 ng/dl, hyperparathyroidism: current
             use of corticosteroids, calcitonin, heparin, phenytoin, phenobarbital, methotrexate,
             bisphosphonates, calcitonin, selective estrogen receptor modulator or PTH)

          -  Use of androgen or estrogen in the preceding year

          -  Use of psychiatric medications including antipsychotic medications and SSRI

          -  Metastatic or advanced cancer (other than skin cancer)

          -  History of breast cancer

          -  Active cardiac ischemia by history of angina or myocardial infarction in the preceding
             6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kenny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut Center on Aging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-5215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>von MÃ¼hlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008 May;19(5):699-707. Epub 2007 Dec 15.</citation>
    <PMID>18084691</PMID>
  </reference>
  <reference>
    <citation>Wang YD, Wang L, Li DJ, Wang WJ. Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL. Cell Mol Immunol. 2006 Feb;3(1):41-5.</citation>
    <PMID>16549048</PMID>
  </reference>
  <reference>
    <citation>Greendale GA, McDivit A, Carpenter A, Seeger L, Huang MH. Yoga for women with hyperkyphosis: results of a pilot study. Am J Public Health. 2002 Oct;92(10):1611-4.</citation>
    <PMID>12356608</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 25, 2008</last_update_submitted>
  <last_update_submitted_qc>April 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anne Kenny, MD, Associate Professor of Medicine</name_title>
    <organization>University of Connecticut Center on Aging</organization>
  </responsible_party>
  <keyword>bone mineral density</keyword>
  <keyword>bone turnover markers</keyword>
  <keyword>strength</keyword>
  <keyword>balance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

